logo
  

Integral Molecular Reaches Antibody License Deal With AstraZeneca For Oncology Therapeutics

Integral Molecular said that it reached an exclusive worldwide antibody license agreement with AstraZeneca (AZN,AZN.L) to develop therapeutics for multiple cancers.

As per the terms of the deal, Integral Molecular will provide an exclusive license to AstraZeneca for a collection of monoclonal antibodies for use in oncology. AstraZeneca will be solely responsible for all research, development, and commercial activities.

The antibodies licensed by AstraZeneca were discovered and characterized using Integral Molecular's platforms designed to yield antibodies against structurally complex membrane proteins.

The MPS Antibody Discovery platform, Lipoparticles, Membrane Proteome Array, and Shotgun Mutagenesis Epitope Mapping technologies were used to generate diverse antibodies with exceptional specificity.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The TJX Companies, Inc. (TJX) said its first-quarter pretax profit margin and earnings per share, each on an adjusted basis, exceeded its plans even though sales were slightly below planned range. Adjusted pretax margin was 9.4%, excluding a 1.9 percentage point charge related to a write-down of the... Apple Inc. is delaying its latest plan to ask employees to come back to the office three days a week, but will continue with its plan of two days in office a week, Bloomberg reported. Citing an internal memo, the report also said the tech major is again requiring its staff to wear masks in common spaces, meeting rooms, hallways, and elevators, as well as at 100 US stores. The U.S. Food and Drug Administration or FDA has urged infant formula manufacturers to import infant formula products to the United States to meet the ongoing severe supply shortage. In order to further increase the availability of infant formula in the country, while protecting the health of infants, the regulator announced a guidance outlining increased flexibilities for the global manufacturers
Follow RTT